Albuminuria and Cardiovascular Risk Assessment

Albuminuria denotes the abnormal presence of albumin in the urine, reflecting early glomerular barrier dysfunction and systemic endothelial injury. It serves not only as a hallmark of renal microvascular damage but also as a potent predictor of cardiovascular events, including hypertension, atherosclerotic disease, heart failure and mortality. Quantification of the urine albumin-to-creatinine ratio (UACR) enables stratification into normoalbuminuria, microalbuminuria and macroalbuminuria, with each category corresponding to an escalating risk profile. International guidelines now recommend routine screening for albuminuria among individuals with diabetes, hypertension or chronic kidney disease, and integration of UACR alongside estimated glomerular filtration rate (eGFR) and traditional risk factors into global risk algorithms. Mechanistically, albuminuria reflects endothelial dysfunction, inflammation and activation of the renin–angiotensin–aldosterone system, all of which contribute to vascular remodelling. Therapeutic interventions that reduce albuminuria, such as renin–angiotensin system blockade and lifestyle modification, have been shown to attenuate cardiovascular risk. Ongoing research continues to elucidate the pathways linking renal microvascular injury with systemic cardiovascular disease, informing novel diagnostic and therapeutic strategies.

Research from Nature Portfolio

Cross-sectional analysis of diabetic patients has characterised the native conformation and serum concentration of α2-macroglobulin, revealing a robust correlation with UACR and arterial stiffness. Multivariate modelling demonstrated that UACR and pulse-wave velocity independently predict circulating α2-macroglobulin levels, suggesting a mechanistic link between albuminuria, protease-inhibitor up-regulation and vascular remodelling that may underlie increased cardiovascular risk.

Albuminuria and Cardiovascular Risk Assessment publication trend

The graph below shows the total number of articles in albuminuria and cardiovascular risk assessment across all publications each year (not limited to Nature Index journals).

Technical terms

Albuminuria: Excess albumin in the urine, indicating glomerular barrier dysfunction and systemic endothelial injury.

Microalbuminuria: Moderate elevation of urinary albumin (30–300 mg per 24 h or equivalent UACR), signifying early renal damage.

Macroalbuminuria: High urinary albumin excretion (>300 mg per 24 h or equivalent UACR), reflecting advanced glomerular injury.

Urine albumin-to-creatinine ratio (UACR): A normalised metric of albuminuria that adjusts for urine concentration.

Estimated glomerular filtration rate (eGFR): A calculation of renal filtration capacity based on serum creatinine.

α2-Macroglobulin: A high-molecular-weight serum protease inhibitor linked to vascular remodelling and cardiovascular risk.

References

1. Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes. Cardiovascular Diabetology (2023).
2. Urinary albumin-to-creatinine ratio as an independent predictor of long-term mortality in atherosclerotic cardiovascular disease patients: A propensity score-matched study UACR and Long-term Mortality in ASCVD. American Journal of Preventive Cardiology (2024).
3. The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLOS Medicine (2008).
4. Molecular form and concentration of serum α2-macroglobulin in diabetes. Scientific Reports (2019).